Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reformulated BeneFIX efficacy and safety after conversion from plasma-derived factor IX
2007-004017-33Phase 4Completed
- Sponsor
- Wyeth
- Start
- Dec 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of coagulation factor ix recombinant in hemophilia B (HB), sponsored by Wyeth. Primary endpoint: Number and location of bleeding episodes. Started Dec 2007; status: completed.
02
Drugs
coagulation factor ix recombinant
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2007-004017-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004017-33.